NCT07255976 Comparison of Effectiveness of Gingival Displacement Using Retraction Cord and Aluminum Chloride Gel
| NCT ID | NCT07255976 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Dow University of Health Sciences |
| Condition | Gingival Bleeding |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2024-09-11 |
| Primary Completion | 2025-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 66 participants in total. It began in 2024-09-11 with a primary completion date of 2025-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the horizontal gingival displacement by using a retraction cord and aluminum chloride gel, and also to determine the time taken for placement and hemorrhage after the procedure by using a retraction cord and aluminum chloride gel. Patients of both genders, age ranges from 18 to 50 years, will be selecting requiring fixed prosthesis with of minimum two abutments. This study divided in two parallel groups of 33 patients in each group.
Eligibility Criteria
Inclusion Criteria: 1. age ranges from 18 to 50 years a fixed prosthesis with minimum of two abutments. 2. minimum of two abutments 3. Finishing line margins will be Equiogingival 4. Clinically healthy gingiva and periodontium. Exclusion Criteria: * 1\. Sub-gingival or supra-gingival margins 2 Periapical pathosis 3. inadequate obturated root canals 4. bleeidng disorder 5.uncontrolled diabetes, 6.hypertension 7.neurological disease
Contact & Investigator
Armeen Fakhur, bds
PRINCIPAL INVESTIGATOR
Dow University of Health Sciences
Frequently Asked Questions
Who can join the NCT07255976 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Gingival Bleeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07255976 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07255976 currently recruiting?
Yes, NCT07255976 is actively recruiting participants. Contact the research team at armeenfakhur.401050@duhs.edu.pk for enrollment information.
Where is the NCT07255976 trial being conducted?
This trial is being conducted at Karachi, Pakistan.
Who is sponsoring the NCT07255976 clinical trial?
NCT07255976 is sponsored by Dow University of Health Sciences. The principal investigator is Armeen Fakhur, bds at Dow University of Health Sciences. The trial plans to enroll 66 participants.